Last Wednesday, August 30th, AMP trimmed its largest position by selling shares in Fibrogen (FGEN). At the time of the sale the position was up more than 150%. FGEN remains the biggest position in the AMP Hypothetical Fund.
Today, AMP also started a position in Nabriva Therapeutics (NBRV) ahead of its Phase 3 Lefamulin - LEAP 1 study readout in Moderate to severe Community Acquired Bacterial Pneumonia (CABP). We are cautiously optimistic about ahead of the results of this study.
Lastly, AMP also added to its CLSD position today by purchasing shares on a down day for the company.